Cancer Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Cancer pain is a common experience for many individuals diagnosed with cancer or undergoing cancer treatment. The primary cause of cancer pain is the tumor, which can compress surrounding tissues such as nerves, bones, spinal cord, and organs. It can also result from diagnostic tests or treatments, such as biopsies, spinal taps, radiation therapy, chemotherapy, and surgery. The pain can be either acute or chronic. Acute pain is typically short-lived due to injury or treatment, while chronic pain can be persistent and may result from nerve changes due to cancer or cancer treatment. The World Health Organization has developed a three-step analgesia guide for cancer pain management, which includes non-opioids, weak opioids, and strong opioids.
·
Pain prevalence rates were 39.3% after
curative treatment; 55.0% during anticancer treatment; and 66.4% in advanced,
metastatic, or terminal disease.
Thelansis’s “Cancer Pain Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Cancer Pain treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
KOLs insights
of Cancer Pain across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Cancer Pain Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment